Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1181-1200 of 1,694 trials

Sarcoidosis: Oral Sirolimus for Facial Skin Involvement

We are studying whether sirolimus can improve facial skin symptoms in patients with sarcoidosis. The trial also examines its effects on quality of life and overall skin health.

Skin Sarcoidosis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesAllergologyDermatology

Progressive Multiple Sclerosis: IMU-838 Study

We are testing a new medication, IMU-838, to see if it helps reduce brain atrophy in patients with progressive multiple sclerosis. This study compares its effects to a placebo to evaluate its safety and tolerability.

Progressive Multiple Sclerosis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Hepatoblastoma and Hepatocarcinoma: Personalized Treatment Study

We are investigating new ways to tailor treatments for children with liver cancer to improve effectiveness and reduce side effects. This study also aims to better understand the genetic features of these tumors.

Hepatoblastoma and Liver CancerConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncologyPediatrics

Reducing Anxiety in Children: Multimedia vs. Midazolam

We are studying whether using an iPad can help reduce anxiety in young children before surgery, compared to traditional medication. This trial focuses on children aged 1 to 8 years undergoing day-care procedures.

Perioperative Anxiety in Children6-12 monthsMonitoring phase (IV)Standard MedicinesCost ReimbursementInternal MedicineOtolaryngologyPediatricsPsychiatry

Arrhythmogenic Cardiomyopathy: Atorvastatin Study

We are evaluating whether atorvastatin can help slow down heart function decline in people with Arrhythmogenic Cardiomyopathy. The study also looks at its safety and effects on heart-related markers.

Arrhythmogenic Cardiomyopathy1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Dazukibart for Idiopathic Inflammatory Myopathies

We are studying the long-term safety and effectiveness of dazukibart in people with dermatomyositis or polymyositis who have completed prior treatment. This research aims to understand how well the medication works in reducing symptoms and improving health.

Idiopathic Inflammatory Myopathy1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesRheumatology

Extensive-Stage Small-Cell Lung Cancer: THOR Trial

We are studying a combination of chemotherapy, pembrolizumab, and olaparib for patients with extensive-stage small-cell lung cancer. The goal is to see if this approach improves survival and response rates compared to standard treatments.

Extensive-Stage Small-Cell Lung Cancer6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Advanced Respiratory Diseases: Inhaled Furosemide and Levodropropizine

We are studying whether inhaled furosemide can help reduce shortness of breath in patients with advanced respiratory diseases. We also want to see if adding oral levodropropizine enhances this effect.

Difficulty Breathing (Dyspnea)Efficacy phase (II)No PlaceboStandard MedicinesInternal MedicinePulmonology

Atrial Fibrillation: IV Flecainide with Ranolazine

We are comparing the effectiveness of a combination of IV flecainide and oral ranolazine against IV flecainide alone for patients with recent onset atrial fibrillation. This study aims to find out which treatment better restores normal heart rhythm.

Atrial Fibrillation (AF)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiology

Alzheimer's Dementia: ITI-1284 for Agitation

We are studying whether ITI-1284 can help reduce agitation in patients with Alzheimer's dementia compared to a placebo. The trial will also assess the safety and tolerability of this new treatment.

Alzheimer's Disease3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Rett Syndrome: Leriglitazone Study for Children

We are testing the safety and effects of a new medication, leriglitazone, in children with Rett Syndrome. The study aims to understand its impact on development and caregiver challenges.

Rett Syndrome1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPediatrics

Irritable Bowel Syndrome: GSL-01-001 Treatment

We are testing a new oral medication for people with Irritable Bowel Syndrome to see if it helps control symptoms like pain and bloating. The study also aims to evaluate its safety and impact on quality of life.

Irritable Bowel Syndrome (IBS)6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterology

Chronic Lymphocytic Leukemia: Venetoclax with Ibrutinib and Rituximab

We are studying a combination of venetoclax, rituximab, and ibrutinib for treatment-naïve patients with chronic lymphocytic leukemia. The aim is to see if this approach can lead to undetectable minimal residual disease.

Chronic Lymphocytic Leukaemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Leukemia: Venetoclax with Stem Cell Transplant

We are evaluating the safety and effectiveness of Venetoclax combined with standard treatment for patients with high-risk MDS, CMML, or sAML undergoing stem cell transplantation. This study aims to improve outcomes and reduce complications during treatment.

Leukemia>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Painful Diabetic Peripheral Neuropathy: VX-993 Study

We are evaluating a new oral medication, VX-993, for people with pain from diabetic peripheral neuropathy. The study aims to determine if it effectively reduces pain and is safe to use.

Diabetic Peripheral Neuropathic Pain3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementDiabetologyNeurology

NPM1-Mutated Acute Myeloid Leukemia: Eltanexor Study

We are evaluating a new drug called eltanexor for patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. The study aims to see if it is safe and effective in treating this condition.

Acute Myeloid LeukemiaEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Juvenile Idiopathic Arthritis: Early Drug Withdrawal Study

We are exploring whether stopping medication early is safe and effective for children with juvenile idiopathic arthritis in remission. This study also aims to identify new biomarkers that may help predict flare-ups after treatment withdrawal.

Juvenile Idiopathic Arthritis3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPediatricsRheumatology

Gout Treatment: Prednisolone vs. Colchicine

We are comparing two medications for treating acute gout attacks to see which one provides better pain relief and improves joint function. This study aims to help patients find more effective treatment options.

Gout>2 yearsMonitoring phase (IV)Standard MedicinesRheumatology

Colorectal Cancer Prevention: Mesalamine for Lynch Syndrome

We are studying whether mesalamine can help prevent colorectal cancer in patients with Lynch syndrome. This trial compares mesalamine to a placebo to see if it reduces the occurrence of tumors.

Lynch Syndrome>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteGastroenterologyOncology

Chronic Low Back Pain: Melatonin Study

We are investigating whether melatonin can help reduce pain in patients with chronic low back pain. Participants will compare its effects to a placebo over six weeks.

Chronic Low Back Pain6-12 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology